Avacta Group Plc (AVCTF)
Company Transformation
Avacta has transformed into a pure-play oncology biotechnology company, divesting its diagnostics businesses to focus on its proprietary pre|CISION peptide drug conjugate platform.
Key Programs and Progress
FAP-Doxorubicin (AVA6000)
Completed Phase Ia dose escalation and opened Phase Ib expansion cohorts
Achieved safety proof of concept by eliminating cardiac toxicity of doxorubicin
Showed promising efficacy in salivary gland cancer with >90% disease control rate and nearly doubled progression-free survival
Expansion cohorts underway in salivary gland cancer, triple-negative breast cancer, and soft tissue sarcoma
Initial data from salivary gland cohort expected late 2025
FAP-Exatecan (AVA6103)
Moved into IND-enabling status with clinical candidate selected
Features new sustained release mechanism (key IP filed September 2024)
IND filing expected late 2025, Phase I trial start Q1 2026
Leverages AI through Tempus collaboration for smarter trial design
Financial Position
Cash of $17.3 million as of April 2025 (following diagnostics divestment)
Cash runway extends into Q1 2026
Exploring NASDAQ dual listing for broader investor access
Actively seeking partnerships for pipeline programs
Strategic Highlights
Tempus collaboration identifies FAP-positive cancers across virtually all solid tumors
New sustained release IP creates platform reset, enabling multiple therapeutic classes beyond cytotoxics
Confidential pipeline with multiple undisclosed programs
Commercial strategy focuses on rare cancer approvals first, then broader indications
Challenges
Shareholders frustrated with share price performance and communication frequency
Need for additional funding to advance programs
Heights Capital convertible bond remains an ongoing issue
Competitive biotech market environment
The company positions itself as having significant long-term value potential through its broad pre|CISION platform, with multiple clinical catalysts expected over the next 1-2 years.